Galcanezumab Looks Promising for Treatment-Resistant Migraine Galcanezumab Looks Promising for Treatment-Resistant Migraine

The calcitonin gene-related peptide monoclonal antibody compared favorably to placebo for reducing the number of average monthly migraine days in a study of people with treatment-resistant migraine.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Source Type: news